Doyoumoney

	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15
Total cash and short-term investments +	140.40	60.21	7.27	13.12	20.30	16.74	13.21	6.89	8.98	2.07	2.01
Cash and cash equivalents	61.83	45.82	7.27	8.19	20.30	16.74	13.21	6.89	8.98	2.07	2.01
Short-term investments	78.57	14.40	0.00	4.93	0.00
Other current assets	0.06	0.08	0.07	0.05	0.22	0.06	0.02	0.43	0.15	0.02	0.02
Total current assets	140.46	60.29	7.33	13.17	20.52	16.80	13.23	7.32	9.13	2.10	2.03
Total non-current assets +	0.25	60,230.78	0.01	0.06	0.00	0.07	0.12	0.41	0.80	0.80	0.80
Property, plant and equipment, net
Goodwill
Intangible assets									730.65
Long-term investments
Other non-current assets
Total assets	140.72	60.29	7.35	13.23	20.52	16.87	13.35	7.32	9.93	2.90	2.83

Total current liabilities +	2.74	5.25	1.76	3.13	1.58	1.18	0.72	0.40	0.31	0.06	0.07
Accounts payable	2.74	2.25	1.76	3.13	1.58	1.18	0.72	0.40	0.31	0.06	0.07
Short-term debt				0.05
Current portion of long-term debt
Deferred revenue
Other current liabilities	2,732.50	3.00	1,757.39	-0.05	1.58	1.18	0.72	0.40	0.31	0.06
Total non-current liabilities +	0.15	0.00	0.00	0.01	1.58	1.18	0.72	0.00	0.00	0.00
Long-term debt
Capital lease obligations	0.15	0.00	0.00	0.01	0.00
Other non-current liabilities
Total liabilities	2.89	5.25	1.76	3.14	1.58	1.18	0.72	0.40	0.31	0.06	0.07

Total stockholders' equity +	137.83	55.04	5.59	10.09	18.94	15.69	12.63	6.92	9.62	2.83	2.75
Common stock and paid-in capital	227.34	130.83	65.79	61.89	60.23	47.88	38.51	28.57	28.05	4.70	3.44
Retained earnings	-89.51	-75.79	-60.21	-51.80	-41.29	-32.19	-25.88	-21.66	-18.43	-1.87	-0.69
Common shares outstanding	7	11	15	13	12	11	11	10	10	10	8

Show Quarterly Balance Sheet

	Mar-26	Dec-25	Sep-25	Jun-25	Mar-25	Dec-24	Sep-24	Jun-24	Mar-24	Dec-23	Sep-23	Jun-23	Mar-23	Dec-22	Sep-22	Jun-22	Mar-22	Dec-21	Sep-21	Jun-21	Mar-21	Dec-20	Sep-20	Jun-20	Mar-20	Dec-19	Sep-19	Jun-19	Mar-19	Dec-18	Sep-18	Jun-18	Mar-18	Dec-17	Sep-17	Jun-17	Mar-17	Dec-16	Sep-16	Jun-16	Mar-16
Total cash and short-term investments +	137.49	140.40	143.68	53.25	54.55	60.21	6,020.08	7.12	8.79	7.27	8.49	10.19	11.68	13.12	14.32	16.46	17.82	20.30	22.34	24.29	25.72	16.74	17.98	12.55	12.59	13.21	4.49	5.13	5.88	6.89	7.62	7.42	8.17	8.98	9.79	3.48	2.07	2.07	0.00	0.00	2.01
Cash and cash equivalents	52.54	61.83	127.68	39.50	39.71	45.82	6.02	6.12	7.81	7.27	5.52	7.21	5.73	8.19	14.32	16.46	17.82	20.30	22.34	24.29	25.72	16.74	17.98	12.55	12.59	13.21	4.49	5.13	5.88	6.89	7.62	7.42	8.17	8.98	9.79	3.48	-2.07	2.07			-2.01
Short-term investments	84.95	78.57	16.00	13.75	14.84	14.40	6,014.06	1.00	0.99	0.00	2.98	2.98	5.95	4.93																							4.15				4.01
Accounts receivable, net																				0.07
Other current assets	0.25	0.06	0.42	0.50	0.52	0.08	0.05	0.06	0.12	0.07	0.07	0.11	0.11	0.05	0.06	0.19	0.19	0.22	0.11	0.10	0.11	0.06	0.10	0.18	0.12	0.02	0.61	0.47	0.47	0.43	0.27	0.23	0.18	0.15	0.02	0.01		0.02
Total current assets	137.74	140.46	144.09	53.75	55.08	60.29	6.07	7.18	8.91	7.33	8.57	10.30	11.78	13.17	14.37	16.65	18.01	20.52	22.45	24.39	25.84	16.80	18.09	12.73	12.72	13.23	5.11	5.60	6.35	7.32	7.89	7.65	8.35	9.13	9.80	3.49	2.07	2.10			2.01
Total non-current assets +	0.24	0.25	0.11	0.12	0.01	0.00	-6,063.58	0.00	0.00	0.01	0.03	0.04	0.05	0.06	0.07	0.08	0.05	0.00	0.07	0.07	0.07	0.07	0.07	0.07	0.12	0.12	0.00	0.00	0.00	1,053.52	0.80	0.80	0.80	0.80	0.80	0.80	-2.07	0.80			-2.01
Property, plant and equipment, net												0.04			0.07	0.08	0.05
Goodwill
Intangible assets																														1,053.52				730.65
Long-term investments
Other non-current assets
Total assets	137.98	140.72	144.20	53.87	55.09	60.29	6.07	7.18	8.91	7.35	8.59	10.34	11.83	13.23	14.45	16.74	18.07	20.52	22.52	24.46	25.91	16.87	18.16	12.80	12.84	13.35	5.11	5.60	6.35	7.32	7.89	8.45	9.15	9.93	10.60	4.29		2.90

Total current liabilities +	2.46	2.74	2.57	1.58	1.49	5.25	1.12	1.09	1.44	1.76	1.98	2.50	2.89	3.13	1.91	2.19	1.07	1.58	1.24	1.10	0.81	1.18	0.61	0.57	0.44	0.72	0.48	0.47	0.58	0.40	0.31	0.32	0.29	0.31	0.34	0.20		0.06
Accounts payable	2.46	2.74	2.54	1.58	1.49	2.25	1.12	1.09	1.44	1.76	1.98	2.50	2.89	3.13	1.91	2.19	1.07	1.58	1.24	1.10	0.81	1.18	0.54	0.53	0.44	0.72	0.48	0.45	0.56	0.40	0.31	0.32	0.29	0.31	0.34	0.20		0.06
Short-term debt			0.03											0.05	0.05								0.07	0.05
Current portion of long-term debt																							0.07	0.05
Deferred revenue
Other current liabilities	2,455.29	2,732.50	2,568.55	1,583.61	1,491.96	3.00	1.12		1,435.16		1,981.80	2,501.82		-0.05	-0.05	2.19	1.07	1.58	1.24	1.10	0.81	1.18	0.54	0.53	0.44	0.72	0.01	0.02	0.02	0.40	0.31	0.32	0.29	0.31
Total non-current liabilities +	0.13	0.15	0.07	0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.02	0.03	0.03	0.00	0.00	0.00	0.00	0.00	0.05	0.08	0.00	0.00	0.00	0.00	0.00
Long-term debt																							0.05	0.08
Capital lease obligations	0.13	0.15	0.07	0.08		0.00				0.00	0.00	0.00	0.00	0.01	0.02	0.03	0.03
Other non-current liabilities
Total liabilities	2.59	2.89	2.64	1.66	1.49	5.25	1.12	1.09	1.44	1.76	1.98	2.50	2.89	3.14	1.94	2.22	1.10	1.58	1.24	1.10	0.81	1.18	0.66	0.65	0.44	0.72	0.48	0.47	0.58	0.40	0.31	0.32	0.29	0.31	0.34	0.20		0.06

Total stockholders' equity +	135.39	137.83	141.56	52.20	53.59	55.04	4.95	6.09	7.48	5.59	6.61	7.84	8.94	10.09	12.51	14.52	16.97	18.94	21.28	23.35	25.10	15.69	17.49	12.15	12.40	12.63	4.62	5.13	5.77	6.92	7.58	8.12	8.86	9.62	10.26	4.09	2.83	2.83			2.75
Common stock and paid-in capital	228.80	227.34	225.87	133.07	132.01	130.83	69.81	69.65	69.32	65.79	65.00	64.28	63.18	61.89	61.42	61.03	60.71	60.23	59.89	59.50	59.17	47.88	47.55	40.57	39.37	38.51	29.30	29.06	28.81	28.57	28.34	28.25	28.16	28.05	27.97	6.93	2.83	4.70	0.00	0.00	2.75
Retained earnings	-93.40	-89.51	-84.31	-80.87	-78.42	-75.79	-64.87	-63.56	-61.85	-60.21	-58.39	-56.44	-54.24	-51.80	-48.91	-46.51	-43.75	-41.29	-38.61	-36.15	-34.07	-32.19	-30.06	-28.42	-26.97	-25.88	-24.67	-23.94	-23.03	-21.66	-20.77	-20.13	-19.30	-18.43	-17.71	-2.84		-1.87
Common shares outstanding	9	7	7	7	7	11	11	18	16	15	14	13	13	13	13	13	13	13	13	13	12	11	11	11	11	11	10	10	9	10	9	9	10	10	10	10	10	9	9	8	8

Balance Sheet - Monopar Therapeutics (MNPR)

Balance Sheet - Monopar Therapeutics (MNPR)